Effects of tafamidis on serial [99mTc]Tc-DPD scintigraphy in transthyretin amyloid cardiomyopathy
Tafamidis in ATTRwt-CM resulted in significant reductions of cardiac [<sup>99m</sup>Tc]Tc-DPD uptake, NYHA class, and cardiac biomarkers at 6 and 12 months. Regression of right ventricular [<sup>99m</sup>Tc]Tc-DPD uptake at 12 months was associated with improved survival.
Authors
- Axel Bauer (ORCID: https://orcid.org/0000-0001-9201-8555)
- Christian Puelacher (ORCID: https://orcid.org/0000-0003-3206-6349)
- Maria Ungericht (ORCID: https://orcid.org/0009-0008-2098-9772)
- Alexander Kroiss
- Thomas Schuetz
- Moritz Messner (ORCID: https://orcid.org/0000-0003-3250-4353)
- Marc‐Michael Zaruba (ORCID: https://orcid.org/0000-0003-1074-5463)
- Simon Staggl (ORCID: https://orcid.org/0000-0003-2489-9869)
- Gerhard Poelzl
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Tirol Kliniken (AT)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1007/s00259-025-07092-7
- Citations
- 5
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- Pfizer